Figure 6
MyoTACTIC cultured hMMTs predict direct effect of chemotherapeutic agents on human skeletal muscle contractile function. (a,c) Representative confocal images of Day 14 hMMTs treated with one-time administration of vehicle (DMSO for Irinotecan and PBS for Gemcitabine) or dosed with (a) Gemcitabine or (c) Irinotecan on Day 7 and then immunostained for sarcomeric α-actinin on Day 14. Scale bar 50 μm. (b,d) Quantification of tetanus (20 Hz electrical stimuli) contractile force generation by Day 14 hMMTs treated with vehicle (DMSO for Irinotecan and PBS for Gemcitabine), (b) Gemcitabine (32 μM and 320 μM), or (d) Irinotecan (16 μM and 72 μM). Values in (b,d) are normalized to vehicle treated results on differentiation day 14. **p < 0.01, ***p < 0.001 (n = minimum of 4 hMMTs from 3 biological replicates per treatment condition). In (b,d) values are reported as mean ± SEM. Significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons to compare differences between groups in (b,d).
